Certara, Inc. (NASDAQ: CERT)

Certara, Inc. is a global leader in biosimulation science technology and consulting services for Model Informed Drug Development serving the biopharmaceutical and biotech industry. The company helps clients use data modeling and analytics to make better decisions during drug research development and commercialization. Its offerings include mechanistic and empirical simulation platforms data management tools and regulatory support services that are used throughout the drug lifecycle.

Certara generates revenue primarily from licensing its proprietary software platforms and from providing technology enabled services and consulting projects. Software sales come from products such as the Simcyp simulator for mechanistic pharmacokinetic analysis the Phoenix PK/PD suite for pharmacokinetic and pharmacodynamic data and the Pinnacle 21 family for clinical data standardization and validation. Service revenue is earned when scientists work with clients to design simulations interpret results prepare regulatory submissions and provide expertise in areas such as quantitative systems pharmacology and regulatory strategy. The company earns fees from its AI enabled offerings such as Certara. AI and the CoAuthor writing tool which help automate document creation and data analysis.

The company operates through the following segments.

• Biosimulation Solutions: This segment provides mechanistic and empirical simulation tools such as the Simcyp simulator for predicting drug absorption distribution and the Phoenix PK/PD suite for analyzing pharmacokinetic and pharmacodynamic data to support dose selection trial design drug interaction studies and includes specialized add ons for biopharmaceutics secondary information and pediatric modeling that extend the platform’s utility across all stages of development.

• Scientific Informatics Solutions: This segment offers chemical property prediction and compound management software obtained through the acquisition of Chemaxon including tools for chemical search registration design and visualization that aid early stage drug discovery and provides workflow integration with the Certara D360 platform to streamline lead optimization and structure activity relationship analysis for biologic candidates.

• Preclinical & Clinical Data Pipeline Solutions: This segment supplies data standardization and validation products like the Pinnacle 21 platform and associated metadata repository and data exchange tools that enable clients to prepare clean analysis ready datasets for regulatory submission and also offers automation solutions for converting study data into the standardized tabular format required by regulators and for managing protocol definitions and metadata across global clinical trials.

• Regulatory Science Solutions: This segment delivers expertise and software for creating and managing regulatory documents including the CoAuthor authoring tool with generative AI and the GlobalSubmit platform for electronic common technical document preparation and submission and also provides regulatory writing consulting and project management services that help clients navigate complex submission requirements for the FDA EMA PMDA and other health authorities.

• Technology Enabled Services: This segment provides consulting and implementation services where Certara scientists apply biosimulation and data analytics to client projects offering support in quantitative systems pharmacology clinical pharmacology drug development strategy and regulatory operations and the team also conducts quantitative systems pharmacology modeling for immunogenicity immuno oncology and neurodegenerative disease programs and assists with the preparation of commercialization plans and post launch evidence generation.

Certara holds a strong position in the biosimulation market where it competes with established technology firms such as Mathworks Dassault Systemes Ansys Simulations Plus and the NONMEM division of ICON as well as with open source tools like R and PK Sim. The company differentiates itself through its scientific expertise proprietary models validated over two decades and its integration of artificial intelligence within expert reviewed workflows that meet regulatory expectations for transparency and reproducibility. Its long standing relationships with major drug regulators including the FDA EMA PMDA and NMPA and its extensive patent portfolio further reinforce its competitive barrier to entry.

Certara serves a diverse customer base that includes more than 2600 biopharmaceutical and biotech companies academic institutions contract research organizations and government agencies across seventy countries. Its software is licensed by over 160000 users and by twenty global drug regulators such as the US Food and Drug Administration the European Medicines Agency Japans Pharmaceuticals and Medical Devices Agency Chinas Center for Drug Evaluation and the UK Medicines and Healthcare Products Regulatory Agency. The company notes that no single customer accounts for more than ten percent of its revenue and its ten largest customers together contributed roughly a quarter of sales in recent years.